A study published in the Annals of Internal Medicine highlights a significant increase in tirzepatide dispensations following its approval, especially among adults with type 2 diabetes and those prescribed weight-lowering medications. The research, which analyzed insurance claims from a large US database, shows that by December 2023, tirzepatide accounted for 12.3% of glucose-lowering medication dispensations among adults with diabetes and 40.6% among adults without diabetes prescribed weight-lowering medications. The study notes a decline in other glucose-lowering and weight-lowering medications, with tirzepatide’s uptake being more rapid and sustained compared to other medications.
Full Story: HealthDay News (4/15)